Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -60.42
- Piotroski Score 2.00
- Grade Buy
- Symbol (ALZN)
- Company Alzamend Neuro, Inc.
- Price $1.33
- Changes Percentage (-2.17%)
- Change -$0.03
- Day Low $1.30
- Day High $1.41
- Year High $19.20
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/01/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.82
- Trailing P/E Ratio -0.32
- Forward P/E Ratio -0.32
- P/E Growth -0.32
- Net Income $-9,947,746
Income Statement
Quarterly
Annual
Latest News of ALZN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Alzamend Neuro, Inc. (ALZN) Stock Price, News, Quote & History - Yahoo Finance
Alzamend Neuro focuses on developing treatments for neurodegenerative and psychiatric disorders, including Alzheimer's and bipolar disorder. Their pipeline includes AL001 and ALZN002, with a partnersh...
By Yahoo! Finance | 2 months ago
